Skip to Main Content

WASHINGTON — A key Senate panel is expanding its plans to punish drug makers that hike prices faster than inflation, according to an internal Senate document described to STAT.

The policy, which is being considered as part of Democrats’ efforts to include drug pricing reforms in a sweeping government spending package, has the potential to change the way drug makers set launch prices for drugs, and how they choose to adjust prices over time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment